NAS:ALNY (USA) Also trade in: Germany UK

Alnylam Pharmaceuticals Inc

$ 68.93 1.02 (1.5%)
Volume: 1,243,097 Avg Vol (1m): 974,939
Market Cap $: 7.34 Bil Enterprise Value $: 6.13 Bil
P/E (TTM): 0.00 P/B: 4.71
Earnings Power Value -80.76
Net Current Asset Value 8.78
Tangible Book 14.68
Projected FCF -21.8
Median P/S Value 63.06
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 41.49
Cash-To-Debt ranked lower than
50.74% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ALNY: 41.49
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 3.29, Med: 108.1, Max: 10000
Current: 41.49
3.29
10000
Equity-to-Asset 0.77
Equity-to-Asset ranked higher than
88.34% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ALNY: 0.77
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.99, Med: 0.67, Max: 0.92
Current: 0.77
-0.99
0.92
Debt-to-Equity 0.02
Debt-to-Equity ranked higher than
91.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ALNY: 0.02
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.07, Med: 0.06, Max: 0.33
Current: 0.02
-0.07
0.33
Debt-to-EBITDA -0.04
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ALNY: -0.04
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.37, Med: -0.06, Max: -0.04
Current: -0.04
-0.37
-0.04
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 6.61
DISTRESS
GREY
SAFE
Beneish M-Score -0.84
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -337.27%
WACC 16.43%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -991.92
Operating Margin ranked lower than
69.95% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ALNY: -991.92
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1087.56, Med: -376.63, Max: -43.72
Current: -991.92
-1087.56
-43.72
Net Margin % -929.51
Net Margin ranked lower than
69.82% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ALNY: -929.51
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1016.58, Med: -367.56, Max: -43.5
Current: -929.51
-1016.58
-43.5
ROE % -52.07
ROE ranked higher than
52.17% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ALNY: -52.07
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -84.12, Med: -39.64, Max: -25.04
Current: -52.07
-84.12
-25.04
ROA % -44.68
ROA ranked higher than
50.55% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ALNY: -44.68
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -48.05, Med: -27.67, Max: -9.19
Current: -44.68
-48.05
-9.19
ROC (Joel Greenblatt) % -313.14
ROC (Joel Greenblatt) ranked higher than
56.18% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ALNY: -313.14
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2120.98, Med: -353.24, Max: -238.93
Current: -313.14
-2120.98
-238.93
3-Year Total Revenue Growth Rate 22.20
3-Year Revenue Growth Rate ranked higher than
69.89% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ALNY: 15.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 3.75, Max: 108
Current: 15.1
0
108
3-Year Total EBITDA Growth Rate -42.90
3-Year EBITDA Growth Rate ranked lower than
56.48% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ALNY: -34.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -65.3, Med: -1.85, Max: 62.2
Current: -34.6
-65.3
62.2
3-Year EPS w/o NRI Growth Rate -29.90
3-Year EPS w/o NRI Growth Rate ranked lower than
60.55% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ALNY: -29.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -52.8, Med: -7.75, Max: 66.7
Current: -29.9
-52.8
66.7

» ALNY's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ALNY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:SRPT NAS:MRNA NAS:IONS NAS:SAGE OCSE:GEN NAS:SGEN NAS:BLUE SZSE:000661 NAS:JAZZ NAS:TECH HKSE:06160 NAS:NBIX HKSE:01177 SZSE:002252 HKSE:02269 TSE:4587 NAS:AMRN XAMS:GLPG NAS:EXEL OCSE:NZYM B
Traded in other countries DUL.Germany 0HD2.UK
Address 300 Third Street, 3rd Floor, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates, including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.

Ratios

Current vs industry vs history
PB Ratio 4.71
PB Ratio ranked lower than
64.14% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ALNY: 4.71
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.07, Med: 5.16, Max: 21.37
Current: 4.71
2.07
21.37
PS Ratio 81.81
PS Ratio ranked lower than
82.51% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ALNY: 81.81
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.1, Med: 74.8, Max: 222.78
Current: 81.81
3.1
222.78
EV-to-EBIT -7.15
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ALNY: -7.15
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -94.6, Med: -13.1, Max: -1.3
Current: -7.15
-94.6
-1.3
EV-to-EBITDA -7.28
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ALNY: -7.28
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -207.5, Med: -14.1, Max: -1.4
Current: -7.28
-207.5
-1.4
EV-to-Revenue 70.99
EV-to-Revenue ranked lower than
77.82% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ALNY: 70.99
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.7, Med: 66.2, Max: 200.5
Current: 70.99
0.7
200.5
Current Ratio 9.33
Current Ratio ranked higher than
83.80% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ALNY: 9.33
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.88, Med: 5.63, Max: 18.24
Current: 9.33
1.88
18.24
Quick Ratio 9.12
Quick Ratio ranked higher than
84.08% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ALNY: 9.12
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.88, Med: 5.63, Max: 18.24
Current: 9.12
1.88
18.24
Days Inventory 952.02
Days Inventory ranked lower than
100.00% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ALNY: 952.02
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 952.02, Med: 2437.52, Max: 2437.52
Current: 952.02
952.02
2437.52
Days Sales Outstanding 142.95
Days Sales Outstanding ranked lower than
100.00% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ALNY: 142.95
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.57, Med: 53.29, Max: 288.31
Current: 142.95
0.57
288.31
Days Payable 1.00
Days Payable ranked lower than
100.00% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ALNY: 1
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 1, Med: 12094.02, Max: 12094.02
Current: 1
1
12094.02

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.90
3-Year Share Buyback Rate ranked higher than
64.29% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ALNY: -5.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -331.8, Med: -12.55, Max: -1
Current: -5.9
-331.8
-1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.70
Price-to-Tangible-Book ranked lower than
55.93% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ALNY: 4.7
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.2, Med: 5.14, Max: 15.16
Current: 4.7
2.2
15.16
Price-to-Median-PS-Value 1.09
Price-to-Median-PS-Value ranked lower than
90.86% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ALNY: 1.09
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 0.39, Max: 2.56
Current: 1.09
0.04
2.56
Earnings Yield (Joel Greenblatt) % -13.92
Earnings Yield (Greenblatt) ranked higher than
51.34% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ALNY: -13.92
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -79.2, Med: -7.6, Max: -1.1
Current: -13.92
-79.2
-1.1

More Statistics

Revenue (TTM) (Mil) $ 86.3
EPS (TTM) $ -7.88
Beta 2.35
Volatility % 49.11
52-Week Range $ 60.27 - 124.22
Shares Outstanding (Mil) 101.18

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N